CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES

被引：1
|
作者：
Bar-Or, A. [1 ]
Fox, R. J. [2 ]
Gold, R. [3 ]
Miller, D. H. [4 ]
Arnold, D. L. [1 ,5 ]
O'Gorman, J. [6 ]
Yang, M. [6 ]
Sheikh, S., I [6 ]
Viglietta, V. [6 ]
Dawson, K. T. [6 ]
Hutchinson, M. [7 ]
机构：
[1] Montreal Neurol Hosp & Inst, Montreal, PQ, Canada
[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[3] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[4] UCL, Inst Neurol, London, England
[5] NeuroRx Res, Montreal, PQ, Canada
[6] Biogen Idec Inc, Weston, MA USA
[7] St Vincents Univ Hosp, Dublin 4, Ireland
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.481
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A102 / A102
页数：1
相关论文
共 50 条
  • [1] An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Miller, D. H.
    Arnold, D. L.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    Hutchinson, M.
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 : S13 - S13
  • [2] Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
    Fox, Robert
    Miller, David
    Phillips, J. Theodore
    Arnold, Douglas
    Selmaj, Krzysztof
    Yang, Minhua
    Zhang, Ray
    Dawson, Katherine
    Viglietta, Vissia
    Sheikh, Sarah
    Gold, Ralf
    [J]. NEUROLOGY, 2013, 80
  • [3] Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
    Bar-Or, Amit
    Fox, Robert
    Gold, Ralf
    Miller, David
    Arnold, Douglas
    O'Gorman, John
    Yang, Minhua
    Sheikh, Sarah
    Viglietta, Vissia
    Dawson, Katherine
    Hutchinson, Michael
    [J]. NEUROLOGY, 2013, 80
  • [4] Clinical and Neuroradiologic Efficacy of BG-12 (Dimethyl Fumarate) in US Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
    Kita, Mariko
    Fox, Robert
    Phillips, J. Theodore
    Arnold, Douglas
    Bar-Or, Amit
    Yang, Minhua
    Zhang, Ray
    Dawson, Katherine
    Viglietta, Vissia
    Sheikh, Sarah
    Gold, Ralf
    [J]. NEUROLOGY, 2013, 80
  • [5] Clinical Efficacy and Safety of Oral Bg-12 (Dimethyl Fumarate) In Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 Define and Confirm Studies
    Bar-Or, A.
    Gold, R.
    Fox, R. J.
    Havrdova, E.
    Selmaj, K.
    Kurukulasuriya, N. C.
    Yang, M.
    Raghupathi, K.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    Phillips, J. T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1828 - 1828
  • [6] Effects of BG-12 (Dimethyl Fumarate) on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
    Kita, Mariko
    Fox, Robert
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Sarda, Sujata
    Kong, Jessica
    Viglietta, Vissia
    Sheikh, Sarah
    Dawson, Katherine
    Kappos, Ludwig
    [J]. NEUROLOGY, 2013, 80
  • [7] Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
    Hutchinson, Michael
    Gold, Ralf
    Fox, Robert
    Havrdova, Eva
    Giovannoni, Gavin
    Zhang, Annie
    Hotermans, Christophe
    Stephan, Monica
    Dawson, Katherine
    Bar-Or, Amit
    [J]. NEUROLOGY, 2013, 80
  • [8] An integrated analysis of the clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies
    Fox, R. J.
    Miller, D. H.
    Phillips, J. T.
    Arnold, D. L.
    Selmaj, K.
    Yang, M.
    Zhang, R.
    Dawson, K. T.
    Viglietta, V.
    Sheikh, S. I.
    Gold, R.
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 : S74 - S74
  • [9] Clinical effects of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Kita, M.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    Hutchinson, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 191 - 191
  • [10] Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM)
    Hutchinson, M.
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Kita, M.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 682 - 683
12345